Home administration of pegfilgrastim reduces disease by 32%, Cigna finds

A Cigna Healthcare study found administering pegfilgrastim, an injection used to prevent infection in cancer patients, in a home setting increased patient outcomes compared to administration in a nonhome setting.

Advertisement

The study, published in the Journal of Clinical Pathways, analyzed data from nearly 13,500 patients who received chemotherapy between Sep. 1, 2020, and Aug. 31, 2022. Patients who underwent home redirection were 32 percent less likely to have incidences of neutropenia, fever, pneumonia and sepsis. 

The odds of same-day pegfilgrastim administration were 43 percent lower in patients who underwent home redirection, according to the study.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.